Company: OCEA
Filing Date: 2025-01-13
Form Type: 10-Q
Source: 0001493152-25-001880
Chunk: 209

Company: Ocean Biomedical, Inc.
Filing Date: 2025-01-13
Form: 10-Q
Item: Item 2
Chunk 209
---
. We do this by leveraging our strong relationships with research universities and medical centers to license their
inventions and technologies with the goal of developing them into products that address diseases with significant unmet medical needs.
We believe that our differentiated business model positions us to capture inventions created at these institutions that might otherwise
fail to be commercialized to benefit patients. Our team of accomplished scientists, business professionals and entrepreneurs bring together
the interdisciplinary expertise and resources required to develop and commercialize a diverse portfolio of assets. We are organized around
a licensing and subsidiary structure that we believe will enable us to create mutual value both for us and potential licensing partners.
We believe this structure, combined with the professional networks of our leadership team members, allows us to opportunistically build
a continuous pipeline of promising product innovations through our existing and potential future relationships with research institutions.

Our
goal is to optimize value creation for each of our product candidates, and we intend to continuously assess the best pathway for each
as it progresses through the preclinical and clinical development process—including through internal advancement, partnerships
with established companies and spin-outs or other strategic transactions—in order to benefit patients through the commercialization
of these products. Our current active assets are licensed from Brown University and Rhode Island Hospital. Our scientific co-founders
and members of our Board of Directors (“Board”), Dr. Jack A. Elias and Dr. Jonathan Kurtis, are both affiliated with Brown
University and with Rhode Island Hospital. Our strategy is to accelerate the flow of the academic discoveries and the required clinical
development required for these product candidates and advance them commercially. The number of potential opportunities at research universities
and medical centers is large, but only a small fraction of these opportunities is currently tapped in the market. The gap remains wide
and we believe this presents an attractive opportunity for us to become an industry leader by addressing a need to accelerate the advancement
of therapeutics that can address significant unmet medical needs. The core elements that we believe differentiate our business model
include:

    ●
    Harnessing inventions
    and technologies from research universities and medical centers. We are experienced at identifying and sourcing breakthrough
    discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.

35

    ●
    Developing new drug
    therapies through an operationally efficient, evidence-based and milestone- driven approach. Once we select an asset for development,
    we pursue what we believe are appropriate development strategies that we aim to execute efficiently by leveraging contract research
    organizations (“C